date:Jun 01, 2012
when the margins are not pharma margins makes this a real challenge for everyone. Such trials do need to be done.
The last thing the industry needs is pre-market approval of efficacy. As someone who has spent most of his life in Europe, the last think you want is an EFSA style pre-market health claims process.
Last week we had a beautiful example of quality science when we covered results of a new study from Sweden that were hailed asresults that cannot be ignoredby Cara Welch, PhD, VP of sci